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Acquired Resistance Mutations to EGFR Treatment in Non-Small Cell Lung 
Cancer 
 
Benjamen Schoenberg and Gregory Omerza  
Clinical Genomic and Molecular Pathology Laboratory, Thomas Jefferson University 
Hospital 
 
Non-small cell lung cancer (NSCLC) is currently the number one cause of cancer 
death in the United States for both men and women.1 Mutations in the epidermal growth 
factor receptor (EGFR) gene are detected in approximately 30% of individuals with 
advanced NSCLC in Asia and 10-15% in Western countries.2 For patients harboring 
activating EGFR mutations, treatment includes the use of first or second-generation 
EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as afatinib, gefitinib, or erlotinib. 
The purpose of this case study is to review the pathophysiology of the progression 
of NSCLC in a 63-year-old non-smoking Caucasian woman. The patient presented with 
worsening back pain for four months, sudden onset of lower extremity weakness, and 
unintentional 20-pound weight loss. Imaging revealed spinal cord compression, a right 
upper lung mass with hilar adenopathy, multiple vertebral metastases, adrenal lesions, 
and a mass in the left lobe of the liver. Transbronchial biopsy of the lung mass in the 
patient confirmed NSCLC of the adenocarcinoma type. Next Generation Sequencing 
(NGS) identified an L858R mutation in exon 21 of EGFR, which results in activation of 
the tyrosine kinase (TK) domain of the EGFR protein product, without the need for 
ligand binding and a decreased binding affinity for ATP. The patient began daily erlotinib 
therapy with subsequent regression of disease at four months follow-up. After 12 months 
on erlotinib the patient developed radiographic progression with a T790M mutation in 
exon 20, the most common resistance mutation secondary to treatment with first 
generation TKIs. The patient was subsequently started on the third-generation TKI, 
osimertinib. After 12 months of treatment the patient developed the EGFR C797S tertiary 
mutation leading to osimertinib resistance and further progression of the disease. 
According to clinical guidelines, all patients with non-squamous NSCLC should 
be tested for mutations in EGFR. This case study serves as evidence that constant 
monitoring of EGFR positive patients is essential, as there are multiple ways in which 
cells develop resistance to TKI treatment.3 
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